These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 22770960)

  • 21. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
    Friedman J; Padget M; Lee J; Schlom J; Hodge J; Allen C
    Oral Oncol; 2019 Mar; 90():38-44. PubMed ID: 30846174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CD137 enhances the efficacy of cetuximab.
    Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
    J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
    Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
    Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
    McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
    Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
    Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
    Parihar R; Trotta R; Roda JM; Ferketich AK; Tridandapani S; Caligiuri MA; Carson WE
    Cancer Res; 2005 Oct; 65(19):9099-107. PubMed ID: 16204085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
    Temam S; Spicer J; Farzaneh F; Soria JC; Oppenheim D; McGurk M; Hollebecque A; Sarini J; Hussain K; Soehrman Brossard S; Manenti L; Evers S; Delmar P; Di Scala L; Mancao C; Feuerhake F; Andries L; Ott MG; Passioukov A; Delord JP
    Ann Oncol; 2017 Nov; 28(11):2827-2835. PubMed ID: 28950289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
    Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
    Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
    Front Immunol; 2021; 12():737311. PubMed ID: 34557197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.
    López-Albaitero A; Ferris RL
    Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1277-81. PubMed ID: 18086972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
    Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
    Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
    Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
    Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
    Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
    Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
    Kondadasula SV; Roda JM; Parihar R; Yu J; Lehman A; Caligiuri MA; Tridandapani S; Burry RW; Carson WE
    Blood; 2008 Apr; 111(8):4173-83. PubMed ID: 18174382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.